The CEO of the Saudi Food and Drug Authority (SFDA), Dr. Hisham bin Saad Aljadhey, held a meeting today with several CEOs from local and international pharmaceutical companies at the SFDA headquarters in Riyadh. The discussions focused on strengthening cooperation and collaboration, exploring strategies to align with the objectives of Saudi Vision 2030, particularly in developing national industries and advancing the SFDA's fourth strategic plan, which prioritizes product safety and aims to enhance product availability.
Dr. Aljadhey highlighted the importance of these meetings in addressing challenges and supporting companies to ensure they meet the requirements necessary to guarantee the availability, safety, and effectiveness of medicines. He emphasized that the SFDA is always open to investors, welcoming their feedback, opinions, inquiries, and comments. The authority is committed to providing comprehensive support to preserve public health by ensuring the safety of medicines available in the Saudi market.
Company representatives commended the high level of transparency maintained by the SFDA, which fosters a collaborative environment between companies and the regulatory body in the Kingdom of Saudi Arabia. They also recognized the significant development the sector has experienced in recent times.
Through its fourth strategic plan, the SFDA aims to empower investors in the pharmaceutical sector, positioning the Kingdom as a global leader in this field. Dr. Aljadhey conducts periodic meetings with food, pharmaceutical, and medical device companies to promote communication and transparency across these sectors.